Literature DB >> 24847409

Scleromyxedema: a case clinically and histologically responsive to intravenous immunoglobulin.

Leslie Caudill1, Eric Howell2.   

Abstract

The authors report a 60-year-old man who presented with a rash and developed ataxia, confusion, slurring of speech, and disorientation that prompted hospitalization. A diagnosis of generalized scleromyxedema with neurological features was eventually made and the patient was treated with intravenous immunoglobulin. The patient showed clinical response to intravenous immunoglobulin therapy, and repeat biopsy showed histological clearance of increased fibroblasts and mucin deposition, demonstrating both clinical and histological response to intravenous immunoglobulin.

Entities:  

Year:  2014        PMID: 24847409      PMCID: PMC4025520     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  7 in total

1.  Scleromyxoedema: a cause for unexplained encephalopathy and myositis.

Authors:  E Tan; N Lau; A Yung
Journal:  Clin Exp Dermatol       Date:  2010-10       Impact factor: 3.470

2.  Scleromyxedema diagnosis following unexplained encephalopathy.

Authors:  Margarida Rodrigues; Alvaro Machado; Filipa Ventura; Maria Luz Duarte; Carla Ferreira
Journal:  Eur J Dermatol       Date:  2007-12-18       Impact factor: 3.328

3.  Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).

Authors:  Marissa Blum; Fredrick M Wigley; Laura K Hummers
Journal:  Medicine (Baltimore)       Date:  2008-01       Impact factor: 1.889

4.  [Efficacy of intravenous immunoglobulin in the treatment of scleromyxoedema].

Authors:  L Sillard; T Passeron; N Cardot-Leccia; C Perrin; J-P Lacour; J-P Ortonne
Journal:  Ann Dermatol Venereol       Date:  2009-12-29       Impact factor: 0.777

Review 5.  Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature.

Authors:  Novie Sroa; Shannon Campbell; Mark Bechtel
Journal:  J Drugs Dermatol       Date:  2010-03       Impact factor: 2.114

Review 6.  Scleromyxedema presenting with neurologic symptoms: a case report and review of the literature.

Authors:  Kathleen Marshall; Stacy A Klepeiss; Michael D Ioffreda; Klaus F Helm
Journal:  Cutis       Date:  2010-03

7.  Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.

Authors:  Jeanmarie B Rey; Rebecca B Luria
Journal:  J Am Acad Dermatol       Date:  2009-02-26       Impact factor: 11.527

  7 in total
  5 in total

1.  Scleroderma Mimickers.

Authors:  Nadia D Morgan; Laura K Hummers
Journal:  Curr Treatm Opt Rheumatol       Date:  2016-02-05

2.  Clinical Characteristics and Treatment Outcomes of Scleromyxedema: A 10-Year Retrospective Survey.

Authors:  Abtin Ansari; Zohre Erfani; Maryam Daneshpazhooh; Leila Mahmoudi; Zahra Saffarian; Kambiz Kamyab; Hamidreza Mahmoudi
Journal:  Case Rep Dermatol       Date:  2022-06-27

3.  Scleromyxedema without Paraproteinemia: Treatment with Thalidomide and Prednisolone.

Authors:  Sara Saniee; Ghazaleh Davarnia
Journal:  Case Rep Dermatol       Date:  2016-11-21

4.  Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.

Authors:  Hadi Rabee; Leeda Tayem; Mohammad Gharbeyah; Dina Abugaber
Journal:  BMC Dermatol       Date:  2020-12-04

5.  Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report.

Authors:  Ruba Y Taha; Saba Hasan; Firyal Ibrahim; Yannick Chantran; Hesham El Sabah; Siveen Sivaraman; Issam Al Bozom; Ahmad Al Sabbagh; Laurent Garderet; Halima El Omri
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.